We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ANI Pharmaceuticals to Report Q1 Earnings: Is a Beat in the Cards?
Read MoreHide Full Article
We expect ANI Pharmaceuticals (ANIP - Free Report) to surpass expectations when it reports first-quarter 2025 results on May 9, before market open. The Zacks Consensus Estimate for the to-be-reported quarter’s revenues is pegged at $179.5 million, while the same for earnings is $1.37 per share. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar)
Year to date, shares of ANI Pharmaceuticals have rallied 32% against the industry’s decline of 2%.
Image Source: Zacks Investment Research
Factors Shaping ANIP's Upcoming Results
ANIP derives revenues primarily from the sales of its rare disease and generics and other pharmaceutical products, including royalties and other product development services.
The company’s revenue growth in the first quarter is likely to have been primarily driven by the rapid uptake of its rare disease products, which include its lead asset, Cortrophin Gel.
Cortrophin Gel sales have risen on the back of increasing demand from new patient starts. The positive trend is expected to have continued in the first quarter.
ANIP’s rare disease products also include two new products, Iluvien and Yutiq, which were added to its commercial portfolio following the acquisition of Alimera Sciences last year.
Incremental sales from Iluvien and Yutiq are likely to have boosted ANIP’s top line in the to-be-reported quarter.
The Zacks Consensus Estimate for ANI Pharmaceuticals’ revenues from the rare disease and brands business is pegged at $87 million.
Revenues from the generic and other segments are likely to have been driven by the company’s newly launched products. On the fourth-quarter 2024 conference call held in February, management stated that strong R&D and commercial productivity mostly continued into the first quarter of 2025.
The Zacks Consensus Estimate for revenues from generic and other businesses is pegged at $105 million.
Increased spending on research and development due to a higher level of activity associated with ongoing and new projects is likely to have spiked operating expenses in the first quarter.
Earnings Surprise History
ANI Pharmaceuticals has an encouraging history of earnings surprises. The company beat on earnings in each of the trailing four quarters, delivering an average surprise of 17.32%. In the last reported quarter, ANIP delivered an earnings surprise of 13.19%.
Our proven model predicts an earnings beat for ANI Pharmaceuticals this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. This is the case here, as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: ANI Pharmaceuticals has an Earnings ESP of +0.86%.
Here are some biotech stocks that also have the right combination of elements to beat on earnings this time around:
CytomX Therapeutics (CTMX - Free Report) has an Earnings ESP of +38.89% and a Zacks Rank #1 at present.
CytomX Therapeutics’ shares have plunged 22.1% year to date. CTMX beat on earnings in three of the trailing four quarters and missed in the other one, delivering an average surprise of 180.70%.
argenx (ARGX - Free Report) has an Earnings ESP of +10.92% and a Zacks Rank #3 at present.
argenx stock has risen 5.7% in the year-to-date period. ARGX beat on earnings in two of the last four quarters and missed in the other two, delivering an average surprise of 345.11%. ARGX is scheduled to report first-quarter results on May 8.
Novavax (NVAX - Free Report) has an Earnings ESP of +495.75% and a Zacks Rank #3 at present.
NVAX stock has decreased 20.3% in the year-to-date period. NVAX beat on earnings in two of the last four quarters and missed in the other two, delivering an average negative surprise of 0.48%. NVAX is scheduled to report first-quarter results on May 8.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
ANI Pharmaceuticals to Report Q1 Earnings: Is a Beat in the Cards?
We expect ANI Pharmaceuticals (ANIP - Free Report) to surpass expectations when it reports first-quarter 2025 results on May 9, before market open. The Zacks Consensus Estimate for the to-be-reported quarter’s revenues is pegged at $179.5 million, while the same for earnings is $1.37 per share. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar)
Year to date, shares of ANI Pharmaceuticals have rallied 32% against the industry’s decline of 2%.
Image Source: Zacks Investment Research
Factors Shaping ANIP's Upcoming Results
ANIP derives revenues primarily from the sales of its rare disease and generics and other pharmaceutical products, including royalties and other product development services.
The company’s revenue growth in the first quarter is likely to have been primarily driven by the rapid uptake of its rare disease products, which include its lead asset, Cortrophin Gel.
Cortrophin Gel sales have risen on the back of increasing demand from new patient starts. The positive trend is expected to have continued in the first quarter.
ANIP’s rare disease products also include two new products, Iluvien and Yutiq, which were added to its commercial portfolio following the acquisition of Alimera Sciences last year.
Incremental sales from Iluvien and Yutiq are likely to have boosted ANIP’s top line in the to-be-reported quarter.
The Zacks Consensus Estimate for ANI Pharmaceuticals’ revenues from the rare disease and brands business is pegged at $87 million.
Revenues from the generic and other segments are likely to have been driven by the company’s newly launched products. On the fourth-quarter 2024 conference call held in February, management stated that strong R&D and commercial productivity mostly continued into the first quarter of 2025.
The Zacks Consensus Estimate for revenues from generic and other businesses is pegged at $105 million.
Increased spending on research and development due to a higher level of activity associated with ongoing and new projects is likely to have spiked operating expenses in the first quarter.
Earnings Surprise History
ANI Pharmaceuticals has an encouraging history of earnings surprises. The company beat on earnings in each of the trailing four quarters, delivering an average surprise of 17.32%. In the last reported quarter, ANIP delivered an earnings surprise of 13.19%.
ANI Pharmaceuticals, Inc. Price and EPS Surprise
ANI Pharmaceuticals, Inc. price-eps-surprise | ANI Pharmaceuticals, Inc. Quote
What Our Model Predicts for ANIP
Our proven model predicts an earnings beat for ANI Pharmaceuticals this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. This is the case here, as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: ANI Pharmaceuticals has an Earnings ESP of +0.86%.
Zacks Rank: ANIP currently carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Other Stocks to Consider
Here are some biotech stocks that also have the right combination of elements to beat on earnings this time around:
CytomX Therapeutics (CTMX - Free Report) has an Earnings ESP of +38.89% and a Zacks Rank #1 at present.
CytomX Therapeutics’ shares have plunged 22.1% year to date. CTMX beat on earnings in three of the trailing four quarters and missed in the other one, delivering an average surprise of 180.70%.
argenx (ARGX - Free Report) has an Earnings ESP of +10.92% and a Zacks Rank #3 at present.
argenx stock has risen 5.7% in the year-to-date period. ARGX beat on earnings in two of the last four quarters and missed in the other two, delivering an average surprise of 345.11%. ARGX is scheduled to report first-quarter results on May 8.
Novavax (NVAX - Free Report) has an Earnings ESP of +495.75% and a Zacks Rank #3 at present.
NVAX stock has decreased 20.3% in the year-to-date period. NVAX beat on earnings in two of the last four quarters and missed in the other two, delivering an average negative surprise of 0.48%. NVAX is scheduled to report first-quarter results on May 8.